Bone resorbing activity and cytokine levels in gingival crevicular fluid before and after treatment of periodontal disease.
BACKGROUND
The aim of the present study was to investigate bone resorption activity (BRA), interleukin-1 alpha (IL-1 alpha), IL-1 beta and interleukin-1 receptor antagonist (IL-1ra) in gingival crevicular fluid (GCF) in sites with no signs of periodontal disease and in sites with horizontal or angular loss of periodontal bone. These assessments were performed before and after periodontal treatment.


METHODS
GCFs were collected from 10 individuals with filter strips from two healthy sites and four sites with deep pathological periodontal pockets, two of which showed horizontal bone loss and two with angular bone loss. All diseased pockets were treated with flap surgery and systemic Doxyferm. Twelve months later GCF was collected again and treatment outcome evaluated. BRA in GCFs was assessed in a bone organ culture system by following the release of (45)Ca from neonatal mouse calvariae. The amounts of IL-1 alpha, IL-1 beta and IL-1ra in GCFs were quantified by enzyme-linked immunosorbent assay (ELISA).


RESULTS
Treatment resulted in reduction of pocket depths with 3.5+/-0.5 mm in sites with angular bone loss and 2.8+/-0.3 mm in sites with horizontal bone loss. Initially, BRA, IL-1 alpha, IL-1 beta and IL-1ra were significantly higher in GCFs from diseased sites compared with healthy sites. No differences in BRA and cytokine levels were seen between GCFs from pockets with horizontal and angular bone losses. The levels of IL-1 alpha, IL-1 beta and IL-1ra were significantly reduced after treatment of diseased pockets. Pocket depths were significantly correlated to BRA only in pre-treatment sites with angular bone loss. BRA was correlated to Il-1 alpha, IL-1 beta, but not to IL-1ra, in diseased sites with angular bone loss, before and after treatment. The reductions of BRA in the individual sites, seen after treatment, were not correlated to the reductions of Il-1 alpha, IL-1 beta or IL-1ra.


CONCLUSIONS
These data show that BRA and cytokine levels are increased in GCFs from sites with periodontal disease and that periodontal treatment results in reduction of the cytokines. Our findings further indicate that IL-1 alpha and IL-1 beta play important roles for the BRA present in GCFs, but that other factors also contribute to this activity.
Holmlund
Anders
A
Department of Periodontology, The County Hospital of Gävle-Sandviken, Centre for Research and Development Uppsala University, Gävleborg, Sweden. anders.holmhund@lg.se
Hänström
Lennart
L
Lerner
Ulf H
UH
D000368:Aged; D016301:Alveolar Bone Loss / Q000276:immunology / Q000628:therapy; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002132:Calcium Radioisotopes; D016207:Cytokines / Q000032:analysis*; D004318:Doxycycline / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D005883:Gingival Crevicular Fluid / Q000737:chemistry / Q000276:immunology*; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1 / Q000032:analysis*; D008297:Male; D051379:Mice; D008875:Middle Aged; D009924:Organ Culture Techniques; D010510:Periodontal Diseases / Q000276:immunology* / Q000628:therapy; D010514:Periodontal Pocket / Q000276:immunology / Q000628:therapy; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors*; D012795:Sialoglycoproteins / Q000032:analysis*; D012886:Skull / Q000378:metabolism; D013524:Surgical Flaps; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D002132:Calcium Radioisotopes; D016207:Cytokines; C507763:IL1RN protein, human; C507764:Il1rn protein, mouse; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D017472:Receptors, Interleukin-1; D012795:Sialoglycoproteins; C025940:bone resorption factor; D004318:Doxycycline